泰能和氨苄西林/舒巴坦治疗鲍曼不动杆菌感染的临床研究

目的　比较泰能和氨苄西林 /舒巴坦治疗鲍曼不动杆菌 (Acinetobacterbaumannii,A baumannii)感染的临床效果和抗生素费用消耗 ,为临床治疗鲍曼不动杆菌感染提供依据。方法　对鲍曼不动杆菌感染的 71例ICU病人进行前瞻性观察 ,分析泰能和氨苄西林 /舒巴坦治疗鲍曼不动杆菌感染病人的临床效果和费用消耗。结果　两种药物在相同时间内治疗有效率没有显著差别 ,而用氨苄西林 /舒巴坦治疗的病人抗生素花费明显低于用泰能治疗的病人 ( 2 113元vs 5 789元 ,P <0 0 0 1) ,且泰能治疗组与抗生素相关住院天数 ( 13 48vs 8 95 ,P =0 0 0 3 )和在ICU的总住院天数 ( 2 8 7vs 13 6,P <0 0 0 1)较长。结论　氨苄西林 /舒巴坦治疗鲍曼不动杆菌感染至少和泰能一样有效 ,且使用氨苄西林 /舒巴坦是一种经济的选择。

A clinical study of A. baumannii infection patients treated with imipenem-cilastatin and ampicillin-sulbactam

Objective To compare treatment outcomes and antibiotic related costs of A. baumannii infection treated with imipenem cilastatin and ampicillin sulbactam and to provide evidence for clinical treatment of A. baumannii infection. Methods A prospective investigation was performed on 71 ICU A. baumannii infection patients treated with imipenem cilastatin and ampicillin sulbactam. The treatment outcomes and antibiotic related costs were also analyzed. Results There was no significant difference between the therapeutic efficacy of these two drugs within the same time limit. The antibiotic related costs of the patients treated with ampicillin sulbactam were significantly lower than those with imipenem cilastatin (2 113 Yuan vs 5 789 Yuan , P <0.001). In addition, compared with patients who received ampicillin sulbactam, those received imipenem cilastatin therapy had a significantly longer antibiotic related length of stay(13.48 vs 8.95, P =0.003) and total ICU stay(28.7 vs 13.6, P <0.001). Conclusion Ampicillin sulbactam is at least as effective as imipenem cilastatin and is a cost effective alternative for treatment of A. baumannii infection.